Overall design | The aim of this study was to gain insights into metabolic changes that relates to the ketamine response in treatment-resistant depression patients. Nine subjects with treatment-resistant depression were included. Using a comprehensive non-targeted metabolomics platform, the correlation between change in baseline peripheral metabolites after a 40 min ketamine infusion followed by recovery (change in metabolites in 24 hrs) with ketamine treatment response were investigated. Then a targeted acylcarnitine platform was used to measure 35 acylcarnitines, focusing on the early (baseline to 40 min) and late changes (100 min to 24 h post-infusion) in acylcarnitines and ketamine response in patients with treatment-resistant depression. |
Citation | Singh B, MahmoudianDehkordi S, Voort JLV, et al. Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: a pilot hypothesis generating study. Psychiatry Res. 2022 Aug;314:114655. |
